



ACCRELIST LTD.
UNEARTHING TOMORROW'S GEM

10 Ubi Crescent, Ubi Techpark Lobby E,
#03-94 Singapore 408564
Tel : (65) 6311 2900
Fax: (65) 6311 2905

For Immediate Release

Accrelist doubles capacity of its medical aesthetics clinic at SingPost Centre



*Dr Terence Tea, Executive Chairman and Managing Director of Accrelist,
at the opening of A.M Aesthetics' SingPost Centre clinic.*

Singapore, 23 September 2021 – Accrelist Ltd. (亚联盛控股公司) (“**Accrelist**”, the “**Company**”, and together with its subsidiaries, the “**Group**”) opened its SingPost Centre clinic at 10 Eunos Road 8, #02-140/141, SingPost Centre, shifting to a larger 2-unit premise within the mall, to meet growing customer demand and provide an enhanced customer experience.

The upgraded clinic features 10 treatment rooms, more than doubling its previous capacity, reflecting the Group's confidence in the long-term prospects of its medical aesthetics business.

Accrelist Medical Aesthetics (“**A.M Aesthetics**”) first acquired a chain of four local clinics in 2018, including the SingPost Centre clinic. Under the leadership of Accrelist's Executive Chairman and Managing Director, Dr Terence Tea, A.M Aesthetics has grown into a network of seven local clinics across Singapore and three overseas branches in Malaysia.

Dr Terence Tea said, “Despite the challenges of COVID-19, we continue to build on our track record for growth in the Group’s medical aesthetics segment. In addition to adding more clinics to our network, we are also steadily expanding existing clinics to enable us to serve more customers.”

The Bedok Mall clinic is also expected to move to a larger space within the mall by the end of October 2021.

The Group also continues to expand its clinical skincare products business through A.M Skincare Pte. Ltd. (“**A.M Skincare**”) to broaden its revenue stream.

A.M Aesthetics generated revenue of S\$6.3 million for the financial year ended 31 March 2021 (“**FY2021**”), an increase of S\$1.3 million or 26.0% from S\$5.0 million for the financial year ended 31 March 2020 (“**FY2020**”).

The Group continues to pursue its expansion plans for its medical aesthetics segment with a measured approach for sustainable growth.

-End-

About Accrelist Ltd. (亚联盛控股公司)

Accrelist Ltd. (“**Accrelist**”) seeks to create long-term value for our shareholders and business partners by unlocking and adding value to the companies we invest in. The Group continues to actively pursue new opportunities with a growing focus on medical aesthetics.

The Group’s wholly owned subsidiary corporations include the Accrelist Medical Aesthetics Group of Companies, branded as A.M Aesthetics, and A.M Skincare Pte. Ltd. (“**A.M Skincare**”).

A.M Aesthetics operates a chain of registered aesthetic medical clinics in Singapore and Malaysia which use state-of-the-art equipment and clinically proven solutions to deliver a wide range of highly reliable and effective treatments.

A.M Skincare is principally involved in the retail sale of pharmaceutical and medical goods. It develops and distributes its own original design manufacturer clinical skincare products (“**ODM**”) with support from South Korean dermatologists alongside other non-ODM products.

In addition, Accrelist holds a 53.07% controlling stake in Jubilee Industries Holdings Ltd. (“**Jubilee**”), a one-stop service provider with two main business segments:

1. Mechanical Business Unit (“**MBU**”) which is engaged primarily in precision plastic injection moulding and mould design and fabrication services; and
2. Electronics Business Unit (“**EBU**”) which distributes integrated electronic components.

Headquartered in Singapore, Jubilee’s production facilities span across Malaysia and Indonesia. Jubilee’s products are sold to customers in Singapore, Malaysia, Indonesia, Vietnam, India, the People’s Republic of China, the United States and various European countries.

For more information, please visit www.accrelist.com.sg

**Issued on behalf of Accrelist Ltd.
By RHT Communications and Investor Relations Pte Ltd**

For media enquiries, please contact:

Elliot Siow

Communications Manager
RHT Communications & Investor Relations Pte. Ltd.
DID: +65 6381 6347
Email: elliott.siew@rhtgoc.com

*This Press Release has been reviewed by the Company's Sponsor, RHT Capital Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**SGX-ST**"). The Sponsor has not independently verified the contents of this Press Release.*

This Press Release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this Press Release including the correctness of any of the statements or opinions made or reports contained in this Press Release.

The contact person for the Sponsor is:-

*Name: Mr Mah How Soon, Registered Professional, RHT Capital Pte. Ltd.
Address: 6 Raffles Quay, #24-02, Singapore 048580
sponsor@rhtgoc.com*